Shanghai Danrui Biopharmaceutical Technology

Shanghai Danrui Biopharmaceutical Technology is a Chinese biotechnology company focused on the development and commercialization of innovative cell therapies for cancer. The company is best known for bringing Provenge (sipuleucel-T), the first FDA-approved autologous cellular immunotherapy for prostate cancer, to the Chinese market. Operating as the Chinese arm of Dendreon Pharmaceuticals under the Sanpower Group, Shanghai Danrui maintains state-of-the-art GMP manufacturing facilities in Shanghai. Its business model integrates R&D, large-scale cell therapy manufacturing, and clinical distribution to address unmet needs in oncology. The company continues to explore the application of its dendritic cell platform for other solid tumor indications.